News
Long-term albumin shows survival benefit in decompensated cirrhosis
AMSTERDAM – The ANSWER study showed long-term albumin administration to patients with decompensated cirrhosis may be seen as a disease-modifying...
News
WHO report sets baseline for viral hepatitis elimination
AMSTERDAM – An estimated 328 million people worldwide were living with chronic hepatitis B or C virus infection in 2015 according to a new report...
Article
Toxicity high for SBRT in centrally-located lung tumors
VIENNA – Stereotactic body radiotherapy (SBRT) proved too toxic for many of patients recruited into a multinational phase II trial with centrally-...
Article
c-Myc could be key to alisertib potential in small-cell lung cancer
VIENNA – The investigational agent alisertib plus paclitaxel improved progression-free survival, compared with paclitaxel plus placebo, in...
Article
Durvalumab could offer option for difficult-to-treat NSCLC
VIENNA – In a heavily pretreated population of patients with non–small-cell lung cancer, the investigational checkpoint inhibitor durvalumab was...
Article
Pembrolizumab proves promising for treating advanced SCLC
VIENNA – One-third of patients with extensive-stage small-cell lung cancer (SCLC) treated with the checkpoint inhibitor pembrolizumab achieved an...
Article
Ganetespib fails to hit mark in phase III NSCLC trial
VIENNA – The addition of ganetespib to docetaxel for the treatment of advanced non–small cell lung cancer (NSCLC) did not live up to its earlier...
Article
Periostin level may indicate upper-airway disease in asthmatics
LONDON – Measuring serum levels of the extracellular protein periostin could help identify patients with asthma who have comorbid upper-airway...
Article
Lung cryobiopsies could reduce need for surgical biopsy
LONDON – The vast majority of surgical lung biopsies currently used to diagnose interstitial lung diseases (ILDs) could be avoided, suggests...
Article
Smoking, vitamin D deficiency linked to early MS disability
LONDON – Severe vitamin D deficiency and current smoking predicted accumulated disability in patients with clinically isolated syndrome, which can...
Article
Fluoxetine fails to slow progressive multiple sclerosis
LONDON – Contrary to expectation of a neuroprotective benefit, fluoxetine does not slow down the progressive phase of multiple sclerosis,...
News
Mobility benefits of MS drug dalfampridine confirmed by patient-reported outcomes
LONDON – After 6 months on extended-release dalfampridine, patients with relapsing-remitting multiple sclerosis reported that their ability to...
News
Alemtuzumab, natalizumab found equally effective for relapsing-remitting MS
Key clinical point:Alemtuzumab and natalizumab are similarly effective at preventing relapse and disability progression in patients with relapsing...
News
ICS/LABA exacerbation benefit outweighs pneumonia risk
Key clinical point: The risk for pneumonia associated with drugs containing inhaled corticosteroids (ICS) is outweighed by the reduction in...